Results 21 to 30 of about 2,196 (157)

Apolipoprotein A-I Mimetic Peptides [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2005
Despite identical amino acid composition, differences in class A amphipathic helical peptides caused by differences in the order of amino acids on the hydrophobic face results in substantial differences in antiinflammatory properties. One of these peptides is an apolipoprotein A-I (apoA-I) mimetic, D-4F.
Mohamad, Navab, G M, Anantharamaiah, Srinivasa T, Reddy, Susan, Hama, Greg, Hough, Victor R, Grijalva, Nicholas, Yu, Benjamin J, Ansell, Geeta, Datta, David W, Garber, Alan M, Fogelman   +10 more
openaire   +2 more sources

Bioenergetic programming of macrophages by the apolipoprotein A-I mimetic peptide 4F [PDF]

Biochemical Journal, 2015
The apoA-I (apolipoprotein A-I) mimetic peptide 4F favours the differentiation of human monocytes to an alternatively activated M2 phenotype. The goal of the present study was to test whether the 4F-mediated differentiation of MDMs (monocyte-derived macrophages) requires the induction of an oxidative metabolic programme.
Geeta, Datta, Philip A, Kramer, Michelle S, Johnson, Hirotaka, Sawada, Lesley E, Smythies, David K, Crossman, Balu, Chacko, Scott W, Ballinger, David G, Westbrook, Palgunachari, Mayakonda, G M, Anantharamaiah, Victor M, Darley-Usmar, C Roger, White   +12 more
openaire   +2 more sources

Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally[S]

Journal of Lipid Research, 2011
To determine if the dose of peptide administered or the plasma level was more important, doses of 0.15, 0.45, 4.5, or 45 mg/kg/day of the peptide D-4F were administered orally or subcutaneously (SQ) to apoliptotein (apo)E null mice.
Mohamad Navab, Srinivasa T. Reddy, G.M. Anantharamaiah, Satoshi Imaizumi, Greg Hough, Susan Hama, Alan M. Fogelman   +6 more
doaj   +1 more source

Regulation of Pattern Recognition Receptors by the Apolipoprotein A-I Mimetic Peptide 4F [PDF]

Arteriosclerosis, Thrombosis, and Vascular Biology, 2012
Objective— The apolipoprotein A-I (apoA-I) mimetic peptide 4F favors the differentiation of human monocytes to an anti-inflammatory phenotype and attenuates lipopolysaccharide (LPS)-induced inflammatory responses. We investigated the effects of LPS on the Toll-like receptor (TLR) signaling pathway in 4F-differentiated monocyte ...
White, C Roger, Smythies, Lesley E, Crossman, David K, Palgunachari, Mayakonda N, Anantharamaiah, G M, Datta, Geeta   +5 more
openaire   +3 more sources

Transgenic tomatoes expressing the 6F peptide and ezetimibe prevent diet-induced increases of IFN-β and cholesterol 25-hydroxylase in jejunum

Journal of Lipid Research, 2017
Feeding LDL receptor (LDLR)-null mice a Western diet (WD) increased the expression of IFN-β in jejunum as determined by quantitative RT-PCR (RT-qPCR), immunohistochemistry (IHC), and ELISA (all P < 0.0001). WD also increased the expression of cholesterol
Pallavi Mukherjee, Greg Hough, Arnab Chattopadhyay, Mohamad Navab, Hannah R. Fogelman, David Meriwether, Kevin Williams, Steven Bensinger, Travis Moller, Kym F. Faull, Aldons J. Lusis, M. Luisa Iruela-Arispe, Kristina I. Bostrom, Peter Tontonoz, Srinivasa T. Reddy, Alan M. Fogelman   +15 more
doaj   +1 more source

Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties

Journal of Lipid Research, 2008
We hypothesize that apolipoprotein A-I (apoA-I) mimetic peptides better mimicking the punctuated α-helical repeats of full-length apoA-I are more anti-inflammatory and anti-atherogenic.
Geoffrey D. Wool, Catherine A. Reardon, Godfrey S. Getz   +2 more
doaj   +1 more source

High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease

Frontiers in Pharmacology, 2016
Apolipoprotein A-I (apoA-I) and high-density lipoproteins (HDL) mediate reverse cholesterol transport out of cells. Furthermore, HDL has additional protective functions, which include anti-oxidative, anti-inflammatory, anti-apoptotic, and vasoprotective
Elizabeth M. Gordon, Debbie M. Figueroa, Amisha V. Barochia, Xianglan Yao, Stewart J. Levine   +4 more
doaj   +1 more source

L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice*

Journal of Lipid Research, 2008
We hypothesized that the apolipoprotein mimetic peptide L-4F, which induces arterial anti-oxidative enzymes and is vasoprotective in a rat model of diabetes, would ameliorate insulin resistance and diabetes in obese mice. L-4F (2 mg/kg/d) administered to
Stephen J. Peterson, George Drummond, Dong Hyun Kim, Ming Li, Adam L. Kruger, Susumu Ikehara, Nader G. Abraham   +6 more
doaj   +1 more source

Apolipoprotein Mimetic Peptides: An Emerging Therapy against Diabetic Inflammation and Dyslipidemia

Biomolecules, 2021
Obesity has achieved epidemic status in the United States, resulting in an increase in type 2 diabetes mellitus, dyslipidemia, and cardiovascular disease.
Paul Wolkowicz, C. Roger White, G. M. Anantharamaiah   +2 more
doaj   +1 more source

Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits

Journal of Lipid Research, 2007
Rabbits on a 1% cholesterol diet received injections of vehicle with or without D-4F or L-4F. After 1 month, the percent of aorta with atherosclerotic lesions was 24 ± 15% (vehicle), 10 ± 6% (D-4F) (P < 0.01 vs. vehicle), and 13 ± 9% (L-4F) (P < 0.05 vs.
Brian J. Van Lenten, Alan C. Wagner, Mohamad Navab, G.M. Anantharamaiah, Susan Hama, Srinivasa T. Reddy, Alan M. Fogelman   +6 more
doaj   +1 more source